Biotech - Oncology
•324 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (324)
%
| Company | Market Cap | Price |
|---|---|---|
|
Lilly's Oncology drugs (Jaypirca, Imlunestrant, Olomorasib) establish a strong cancer portfolio.
|
$789.93B |
$833.49
-2.86%
|
|
Company's oncology-focused biotech portfolio and cancer therapies (e.g., CAR-VYKTI, bispecifics) represent a major product category.
|
$458.89B |
$190.72
-0.67%
|
|
AbbVie’s oncology growth driver includes therapeutics (e.g., Venclexta) and an oncology ADC/bispecific pipeline.
|
$431.71B |
$236.56
-1.80%
|
|
AZN operates as a leading Biotech - Oncology company with a broad cancer drug franchise and pipeline.
|
$262.04B |
$84.53
-1.28%
|
|
Novartis' oncology portfolio (Kisqali, Scemblix, Pluvicto) is a core revenue driver and growth engine.
|
$252.00B |
$130.00
|
|
Biotech - Oncology category captures Merck's oncology-focused biotech assets and pipeline beyond Keytruda.
|
$200.78B |
$79.96
-0.16%
|
|
Amgen has a strong oncology pipeline and marketed cancer therapies (IMDELLTRA, BiTE/BLINCYTO) underpining its Biotech - Oncology focus.
|
$156.00B |
$290.13
-2.04%
|
|
Gilead has a deep oncology franchise through Trodelvy and a broader strategy into cancer therapies.
|
$145.76B |
$117.18
-0.40%
|
|
Intera Oncology hepatic artery infusion pump aligns with oncology device/therapy solutions.
|
$141.15B |
$95.41
-1.94%
|
|
Pfizer has a broad oncology franchise and pipeline, including ADC- and immuno-oncology assets.
|
$137.19B |
$24.09
-0.15%
|
|
A number of oncology-focused programs (e.g., BTK inhibitors, radioligand therapies) position Sanofi in Biotech - Oncology.
|
$120.19B |
$98.46
|
|
Opdivo and the oncology Growth Portfolio are core to Bristol-Myers Squibb's business.
|
$89.46B |
$43.96
-1.83%
|
|
Biotech - Oncology captures GSK's focus on cancer therapies, including ADCs and related modalities.
|
$88.43B |
$21.73
|
|
Zoetis' pipeline includes oncology-focused therapies for animals.
|
$62.82B |
$141.11
-1.59%
|
|
Robust oncology pipeline (bispecifics, IO therapies) places Regeneron squarely in Biotech - Oncology.
|
$60.96B |
$564.63
-0.82%
|
|
Oncology is a core therapeutic area with targeted therapies and biologics in Takeda's portfolio.
|
$43.58B |
$27.33
-2.62%
|
|
FRUZAQLA is an oncology therapy, placing Takeda in the Biotech - Oncology category.
|
$43.47B |
$13.71
-1.01%
|
|
BeOne Medicines is an oncology-focused biotech company delivering cancer therapies, including BRUKINSA and TEVIMBRA.
|
$34.59B |
$320.10
-3.00%
|
|
The company has a strong focus on oncology with mRNA-based immunotherapies and cancer vaccines, positioning it in Biotech - Oncology.
|
$24.47B |
$102.06
-2.54%
|
|
Signatera is an oncology-focused diagnostic, aligning with the Biotech - Oncology investable theme.
|
$22.07B |
$161.61
+0.94%
|
|
Genmab operates as a biotechnology company focused on oncology with proprietary antibody platforms and therapies.
|
$21.05B |
$31.81
-0.28%
|
|
Genmab is a oncology-focused biotechnology company, generating revenue from cancer therapeutics (EPKINLY, Tivdak) and a pipeline centered on anticancer biologics.
|
$19.49B |
$315.00
|
|
Monjuvi and other hematology/oncology programs place Incyte in oncology/hematology as a primary focus.
|
$16.22B |
$83.80
-1.42%
|
|
Summit's direct product focus is ivonescimab in oncology, licensed for development and commercialization, making Biotech - Oncology a core segment.
|
$15.86B |
$21.35
-6.28%
|
|
The company operates within oncology diagnostics and biotech-driven test development, aligning with Biotech - Oncology.
|
$11.01B |
$58.34
-2.11%
|
|
Exelixis develops oncology-focused biotech therapies, including small-molecule TKIs and antibody-based modalities within cancer.
|
$10.40B |
$38.15
-1.34%
|
|
The company maintains a significant oncology pipeline featuring personalized neoantigen therapies (INT, mRNA-4157) and related immuno-oncology approaches, representing direct oncology therapeutics.
|
$10.38B |
$26.83
-3.42%
|
|
Blueprint Medicines operates as a biotech company focused on oncology/targeted therapies, aligning with 'Biotech - Oncology'.
|
$8.27B |
$129.46
|
|
Oncology assets like Zanidatamab and Zepzelca anchor Jazz's cancer franchise.
|
$7.99B |
$129.59
-0.16%
|
|
Revolution Medicines focuses on oncology with a pipeline of RAS(ON) inhibitors and has clinically advanced small-molecule cancer therapies (e.g., daraxonrasib, elironrasib, zoldonrasib).
|
$7.92B |
$42.51
-1.41%
|
|
Halozyme's ENHANZE subcutaneous drug-delivery platform enables oncology therapeutics with rapid, high-volume subcutaneous administration and royalties from major cancer products.
|
$7.90B |
$64.10
-2.20%
|
|
Relacorilant and ROSELLA-related oncology data position Corcept in the oncology/biotech investment theme.
|
$7.84B |
$73.96
-15.51%
|
|
Oncology focus through CAR-T and cancer-related gene-editing therapies.
|
$6.31B |
$73.07
-5.51%
|
|
Nuvalent is a clinical-stage oncology biotech focused on developing targeted cancer therapies, aligning with Biotech - Oncology.
|
$5.84B |
$81.39
+4.24%
|
|
Legends' product focus is oncology, with multiple myeloma CAR-T therapy as the flagship.
|
$5.82B |
$31.70
-1.22%
|
|
KB707 immunotherapy for solid tumors places Krystal in oncology biotech.
|
$5.24B |
$181.47
-4.43%
|
|
Core oncology biotechnology company focused on multispecific antibody therapeutics (BIZENGRI and petosemtamab) used for cancer.
|
$4.71B |
$69.05
+1.40%
|
|
Focused on oncology indications (e.g., multiple myeloma) through cell therapies, aligning with cancer biotech therapeutics.
|
$4.52B |
$82.10
+3.69%
|
|
NDC candidate targeting SST2 for SST2-expressing tumors indicates oncology applications.
|
$4.08B |
$42.32
-2.74%
|
|
SRRK's SRK-181 and oncology-facing programs place the company in oncology pipelines.
|
$3.75B |
$39.46
-3.94%
|
|
Oncology-focused diagnostics/theranostics assets align LNTH with cancer-related biotech themes.
|
$3.68B |
$53.23
+2.54%
|
|
Biotech - Oncology: The company has an oncology-focused pipeline and marketed cancer therapies.
|
$3.52B |
$46.99
|
|
Zai Lab's portfolio and late-stage pipeline are heavily oncology-focused with potential blockbusters and China/global development.
|
$3.43B |
$31.62
+0.86%
|
|
The company focuses on oncology radiopharmaceuticals, a core Biotech-Oncology segment.
|
$3.35B |
$10.00
|
|
Directly develops oncology-focused biologic/cancer therapy (cretostimogene) used to treat bladder cancer.
|
$3.30B |
$43.25
-3.74%
|
|
HMDCF is a biotechnology company with a core focus on oncology, developing differentiated targeted cancer therapies.
|
$3.15B |
$3.66
|
|
Centessa is advancing oncology-focused therapies via the LockBody platform.
|
$2.98B |
$22.31
-2.75%
|
|
Ascentage Pharma’s core business is oncology-focused biotechnology with approved and pipeline small-molecule cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$2.75B |
$34.94
-5.05%
|
|
Lead product ANKTIVA is an oncology immunotherapy (cytokine fusion protein) and core revenue driver.
|
$2.40B |
$2.54
+0.20%
|
|
Focus on cancer detection/diagnostics places GRAIL in Biotech - Oncology category.
|
$2.38B |
$66.13
-7.38%
|
|
IDEAYA develops targeted cancer therapies and biomarker-driven precision oncology platforms, fitting Biotech - Oncology.
|
$2.30B |
$26.24
-2.42%
|
|
Strategic emphasis on oncology programs and indications aligns with an oncology-focused biotech portfolio.
|
$2.25B |
$34.10
+0.86%
|
|
Company's core oncology MRD diagnostics (clonoSEQ) and immune medicine platform target cancer monitoring and treatment.
|
$2.03B |
$13.36
-3.68%
|
|
Strategic focus on oncology programs within the biotech/pharmaceutical pipeline (precision oncology).
|
$2.02B |
$4.81
-3.99%
|
|
Cogent Biosciences is advancing precision oncology therapies, focusing on genetically defined cancers and oncogenic drivers.
|
$1.85B |
$16.27
|
|
Gedatolisib is a pan-PI3K/mTOR inhibitor targeting oncology indications, aligning with Biotech - Oncology as the direct product category.
|
$1.74B |
$46.07
-6.25%
|
|
KIMMTRAK is a leading oncology therapy (metastatic uveal melanoma) and Immunocore is expanding an ImmunTAX-based oncology pipeline, making Biotech - Oncology the core investable theme.
|
$1.72B |
$34.27
-0.95%
|
|
Biotech - Oncology focus with ADCs and cancer-targeted modalities in the pipeline.
|
$1.61B |
$15.80
-9.97%
|
|
Arcus Biosciences operates as a oncology-focused biotech developing cancer therapies (HIF-2α inhibitor casdatifan and IO antibodies).
|
$1.55B |
$14.60
-4.20%
|
|
NovoCure's TTFields oncology therapy platform is used to treat multiple cancer indications, aligning with Oncology-focused biotech/device ecosystems.
|
$1.50B |
$13.49
-5.99%
|
|
Preclinical oncology TCE programs and oncology focus indicate an oncology Biotech segment.
|
$1.45B |
$5.03
+2.86%
|
|
Core focus on oncology therapeutics (tumor-activated immunotherapies) under Biotech - Oncology.
|
$1.45B |
$24.44
+3.25%
|
|
The company operates in oncology/hematology with two approved cancer therapies, aligning with 'Biotech - Oncology'.
|
$1.38B |
$16.06
-1.35%
|
|
Nuvation Bio is developing oncology therapies (IBTROZI and Safusidenib) and has a pipeline focused on cancer indications.
|
$1.27B |
$3.74
-1.84%
|
|
The company is a oncology-focused biotech with leading cancer therapeutics such as zanidatamab and an ADC/MSAT pipeline.
|
$1.26B |
$18.06
+4.39%
|
|
Immunome operates as a biotechnology company focused on oncology, aligning with the Biotech - Oncology category.
|
$1.21B |
$13.92
-5.18%
|
|
CureVac's pipeline centers on oncology immunotherapies and cancer vaccines (off-the-shelf and personalized), aligning with Biotech - Oncology.
|
$1.21B |
$5.38
-0.74%
|
|
Company operates in oncology diagnostics; classification under biotech-oncology.
|
$1.17B |
$9.10
+1.56%
|
|
NBTXR3 is an oncology nanotherapeutic asset, directly produced/distributed by Nanobiotix as a lead product.
|
$1.12B |
$23.60
-10.91%
|
|
Relay Therapeutics is a oncology-focused biotechnology company developing cancer therapies, directly aligning with Biotech - Oncology.
|
$1.11B |
$6.50
-5.80%
|
|
NKTR-255 IL-15 agonist with oncology-focused combination strategies indicates biotech oncology focus.
|
$1.08B |
$58.85
+2.65%
|
|
Company focuses on oncology immunotherapies, aligning with Biotech - Oncology.
|
$1.07B |
$10.36
-5.39%
|
|
Company develops oncology therapeutics (taletrectinib and safusidenib) and is active in cancer drug development, fitting Biotech - Oncology.
|
$1.02B |
$3.20
+5.26%
|
|
ORIC is a clinical-stage oncology-focused biotechnology company with lead cancer therapies (ORIC-944, ORIC-114) and an oncology-focused development roadmap.
|
$972.48M |
$13.68
-2.84%
|
|
Enliven Therapeutics is a biotech focused on oncology with lead oral small molecule inhibitors, placing it in Biotech - Oncology.
|
$962.25M |
$19.61
-2.34%
|
|
PRGN-2009/other oncology-focused programs place Precigen in Biotech - Oncology.
|
$959.34M |
$3.25
-3.85%
|
|
Lead candidate ficerafusp alfa is an oncology biotech therapy targeting EGFR and TGF-β, placing Bicara squarely in Biotech - Oncology.
|
$929.30M |
$17.04
+1.97%
|
|
Kura Oncology is a focused oncology biotech developing ziftomenib and other cancer therapies, directly aligning with Biotech - Oncology.
|
$852.76M |
$9.85
-4.09%
|
|
Geron focuses on oncology therapeutics (RYTELO/imetelstat) for hematologic cancers, placing it in Biotech - Oncology.
|
$808.89M |
$1.27
+0.39%
|
|
URGN's core business is oncology-focused biotech/drug development, including UGN-102 (ZUSDURI) and pipeline assets.
|
$802.27M |
$17.40
+0.87%
|
|
Tango Therapeutics is a clinical-stage biotechnology company focused on precision oncology, developing novel cancer therapies (synthetic lethality and immune evasion) with lead small-molecule inhibitors.
|
$773.93M |
$7.14
-3.64%
|
|
Biotech - Oncology: radiopharmaceutical/isotope-based oncology applications.
|
$760.38M |
$10.13
+14.21%
|
|
Olema focuses on oncology-focused biotechnology, aligning with Biotech - Oncology.
|
$759.48M |
$11.10
-0.36%
|
|
Oncology pipeline centered on dual-masked T-cell engagers targeting HER2, PSMA, and EGFR, a core cancer therapeutics business.
|
$758.93M |
$5.49
+5.98%
|
|
Pipeline includes oncology-focused CAR-T cell therapies (SC262, SC291) and other cancer immunotherapies.
|
$753.35M |
$3.34
-1.47%
|
|
Nurix is a clinical-stage oncology-focused biotech developing targeted protein degradation therapies (BTK degraders) for cancer.
|
$746.15M |
$9.76
+0.51%
|
|
Company focuses on oncology therapeutics using TIL cell therapy for solid tumors.
|
$737.99M |
$2.25
+2.04%
|
|
Pipeline and focus are oncology-centric, including tumor-targeted bispecifics and solid-tumor programs.
|
$735.19M |
$10.33
-0.29%
|
|
OJEMDA (tovorafenib) is a systemic oncology therapy directly developed and commercialized by the company.
|
$733.86M |
$7.24
-3.34%
|
|
Biotech - Oncology: diagnostics and tests focused on cancer risk, profiling, and management.
|
$709.77M |
$7.72
+0.78%
|
|
TYRA Biosciences is a clinical-stage biotech focused on oncology therapies, notably selective FGFR inhibitors.
|
$689.72M |
$12.97
+3.10%
|
|
ERAS is a biotech company focused on oncology; its core mission and pipeline target cancer therapies, placing it under Biotech - Oncology.
|
$685.56M |
$2.42
+13.08%
|
|
Biotech - Oncology focus due to cancer drug development pipeline (FID-007, FID-022).
|
$685.29M |
$22.51
-1.01%
|
|
TERN-701 targets BCR-ABL in CML, placing the company in Oncology-focused biotech.
|
$680.36M |
$7.61
-2.31%
|
|
ArriVent BioPharma develops oncology therapeutics, including lead asset firmonertinib, placing it in Biotech - Oncology.
|
$678.78M |
$19.84
+5.42%
|
|
Company's focus centers on oncology-related diagnostics (dermatologic cancers, Barrett's esophagus), placing it in biotech oncology diagnostics.
|
$666.37M |
$23.08
-3.11%
|
|
Elritercept program for myelodysplastic syndromes (MDS) places the company in oncology/hematology-focused therapeutics.
|
$637.66M |
$15.70
-2.73%
|
|
Company focuses on oncology programs using Molecular Glue Degraders (MGDs), aligning with Biotech - Oncology.
|
$617.56M |
$10.04
+17.02%
|
|
CMPX operates as Biotech - Oncology, developing cancer immunotherapies and targeted antibodies.
|
$586.32M |
$4.24
+4.18%
|
|
Company focuses on proprietary oncology therapeutics using Bicycle molecule platform.
|
$576.19M |
$8.32
-7.25%
|
Showing page 1 of 4 (324 total stocks)
Loading industry metrics...
Loading comparison data...
